Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH.
Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 24 | -0.33 Increased by +28.26% | -0.18 Decreased by -83.33% |
| May 7, 24 | 0.34 Increased by +143.04% | 0.05 Increased by +580.00% |
| Feb 27, 24 | -0.50 Increased by +34.21% | -0.48 Decreased by -4.17% |
| Nov 7, 23 | -0.37 Increased by +54.32% | -0.43 Increased by +13.95% |
| Aug 1, 23 | -0.46 Increased by +56.19% | -0.61 Increased by +24.59% |
| May 9, 23 | -0.79 Increased by +15.05% | -0.65 Decreased by -21.54% |
| Feb 21, 23 | -0.76 Increased by +57.06% | -0.84 Increased by +9.52% |
| Nov 1, 22 | -0.81 Increased by +69.08% | -0.92 Increased by +11.96% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 51.63 M Increased by +52.00% | -29.52 M Increased by +28.43% | Decreased by -57.18% Increased by +52.91% |
| Jun 30, 24 | 73.83 M Increased by +186.33% | -61.92 M Decreased by -24.01% | Decreased by -83.87% Increased by +56.69% |
| Mar 31, 24 | 137.74 M Increased by +466.14% | 61.02 M Increased by +168.39% | Increased by +44.30% Increased by +112.08% |
| Dec 31, 23 | 32.25 M Increased by +71.38% | -56.34 M Increased by +17.70% | Decreased by -174.71% Increased by +51.98% |
| Sep 30, 23 | 33.97 M Increased by +78.97% | -41.25 M Increased by +39.88% | Decreased by -121.43% Increased by +66.41% |
| Jun 30, 23 | 25.79 M Increased by +36.86% | -49.94 M Increased by +37.79% | Decreased by -193.65% Increased by +54.55% |
| Mar 31, 23 | 24.33 M Increased by +29.16% | -89.22 M Decreased by -26.60% | Decreased by -366.72% Increased by +1.98% |
| Dec 31, 22 | 18.82 M Increased by +22.19% | -68.46 M Decreased by -5.13% | Decreased by -363.81% Increased by +13.96% |